Imunon Inc (IMNN)
1.36
0.00 (0.00%)
USD |
NASDAQ |
Jul 08, 16:00
1.36
0.00 (0.00%)
After-Hours: 20:00
Imunon SG&A Expense (Annual): 9.743M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
Date | Value |
---|---|
December 31, 2023 | 9.743M |
December 31, 2022 | 13.69M |
December 31, 2021 | 10.89M |
December 31, 2020 | 7.642M |
December 31, 2019 | 8.000M |
December 31, 2018 | 9.700M |
December 31, 2017 | 5.890M |
December 31, 2016 | 6.527M |
December 31, 2015 | 6.687M |
December 31, 2014 | 8.860M |
December 31, 2013 | 6.547M |
December 31, 2012 | 6.373M |
December 31, 2011 | 5.155M |
December 31, 2010 | 4.923M |
Date | Value |
---|---|
December 31, 2009 | 3.327M |
December 31, 2008 | 2.043M |
December 31, 2007 | 5.354M |
December 31, 2006 | 3.723M |
December 31, 2005 | 3.405M |
December 31, 2004 | 3.471M |
September 30, 2003 | 5.126M |
September 30, 2002 | 4.833M |
September 30, 2001 | 3.212M |
September 30, 2000 | 2.661M |
September 30, 1999 | 1.40M |
September 30, 1998 | 2.516M |
September 30, 1997 | 2.283M |
September 30, 1996 | 1.338M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
7.642M
Minimum
2020
13.69M
Maximum
2022
9.992M
Average
9.743M
Median
2023
SG&A Expense (Annual) Benchmarks
iBio Inc | 19.02M |
Ocugen Inc | 31.99M |
Avalo Therapeutics Inc | 10.30M |
Petros Pharmaceuticals Inc | 9.262M |
NovaBay Pharmaceuticals Inc | 12.83M |